Latest Adverse effect Stories
Monitoring pain and providing analgesics to patients in intensive care units (ICUs) during non-surgical procedures, such as turning and washing, can not only reduce the amount of pain but also reduce the number of serious adverse events including cardiac arrest, finds new research in BioMed Central's open access journal Critical Care. Although pain at rest is routinely noted, pain during procedures is less regularly reported and its effect on patients unknown. To assess this missing...
HENDERSON, Nev., April 10, 2013 /PRNewswire-USNewswire/ -- Green Valley Drugs is voluntarily recalling All Lots of All Sterile products compounded, repackaged, and distributed by the pharmacy due to lack of sterility assurance and concerns associated with the quality control processes. A full list of the recalled products is attached to this press release and can be accessed at greenvalleymed.com. The recall of sterile products is conducted based on observations of clean room...
OXFORD, England, March 25, 2013 /PRNewswire/ -- Senior researchers at Oxford University's Clinical Trial Service Unit welcomed today's statement by the Principal Investigators of the AIM-HIGH trial about the consistency of the adverse effects seen in the AIM-HIGH trial of extended-release niacin (Niaspan) with those reported from the HPS2-THRIVE trial of extended-release niacin given in combination with laropiprant (Tredaptive). The findings of the HPS2-THRIVE trial of...
Recently, the law firm of d’Oliveira & Associates, has announced a “No Win, No Fee Promise” to any clients that have suffered any of the side effects of Xarelto and may be entitled to compensation. (PRWEB) March 12, 2013 Xarelto is an anticoagulant that is manufactured by the Johnson & Johnson subsidiary, Janssen Pharmaceuticals. Approved by The U.S. Food and Drug Administration in just 2011, the drug was intended to act as a blood thinner to help prevent blood clots and...
OTTAWA, March 7, 2013 /CNW/ - Following the death of a child enrolled in a clinical trial for the drug Sensipar in the United States, Health Canada is reminding healthcare professionals and consumers that Sensipar is not approved for use in patients under 18 years of age. Sensipar (cinacalcet) is used for treating disorders of the parathyroid gland that result in high blood calcium levels. Amgen, the manufacturer of Sensipar, recently halted all pediatric clinical trials of...
redOrbit Staff & Wire Reports - Your Universe Online Two pharmaceutical companies have issued a recall of their anemia drug Omontys after receiving reports that some kidney dialysis patients had suffered severe allergic reactions after taking the medication. According to the Associated Press (AP), California-based Affymax Inc. and Illinois-based Takeda Pharmaceutical Co. said some of the more than 25,000 patients who had received the drug had experienced adverse effects afterwards,...
OTTAWA, Feb. 22, 2013 /CNW/ - The issue: Two unauthorized health products "18 Again" and "Stiff 4 Hours" were tested by Health Canada and were found to contain hidden ingredients (sildenafil or tadalafil) that may pose serious risks to the health of Canadians. The products were being sold at the Unchained Romance booth at the 12(th) Annual Vancouver Taboo Sex Show. These products are promoted as male sexual stimulants and contain hidden prescription medications. Approved...
SPRINGFIELD, Pa., Feb. 15, 2013 /PRNewswire/ -- Reumofan Plus USA, LLC and Reumofan USA, LLC is recalling "Reumofan Plus" Tablets, Lot# 99515, exp. 09/16, because they contain undeclared active pharmaceutical ingredients: methocarbamol, dexamethasone, and diclofenac. Use of this product could result in serious and life-threatening injuries. Reumofan Plus is used as a treatment for muscle pain, arthritis, osteoporosis, bone cancer and other conditions. This product comes in...
OTTAWA, Jan. 30, 2013 /CNW/ - The issue: Arbonne International Distribution Inc. is voluntarily recalling one lot (lot 043904) of its RE9 Advanced for Men Facial Moisturizer SPF 20 Sunscreen due to microbial contamination. Product testing undertaken by the company detected bacteria (Aerococcus viridans) that may pose serious health risks to people, especially those with weakened immune systems. Who is affected: Canadians, who have purchased or used this product, especially...
Standard will be supported by marketing activities to boost reporting by health professionals OTTAWA, Jan. 30, 2013 /CNW/ - The Honourable Leona Aglukkaq, Minister of Health, today congratulated Accreditation Canada on including, for the first time, guidance on the reporting of adverse drug reactions in its latest Medication Management Standards for health care facilities, including hospitals. "Our Government is committed to protecting the health and safety of Canadians,"...
